Literature DB >> 12232042

A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.

Jeffrey D Ahlers1, Igor M Belyakov, Masaki Terabe, Rima Koka, Debra D Donaldson, Elaine K Thomas, Jay A Berzofsky.   

Abstract

Although a role for CD4(+) helper cells in CD8(+) cytotoxic T lymphocyte (CTL) induction by vaccines is widely recognized, much less is known about a counterbalancing role of CD4(+) T cells in down-modulating this response, or about ways to optimize vaccine responses through abrogation of this negative regulatory mechanism. Here, we discovered a synergistic enhancement of vaccine-mediated CTL induction and protection by the relief of suppression through depletion of regulatory CD4(+) cells, including CD4(+) NKT cells, or blockade of IL-13 made by these cells, combined with the cytokine granulocyte/macrophage colony-stimulating factor and the costimulatory molecule CD40L. Indeed, in the absence of helper epitopes, granulocyte/macrophage colony-stimulating factor and the helper-mimetic molecule CD40L are not sufficient to replace help to induce CTL without abrogation of CD4(+) T cell-mediated suppression, suggesting a role for T cell help in overcoming suppression. The increased CTL induction translated to striking protection against viral infection by a vaccine by using this synergistic combined approach. These results argue for a push-pull approach to maximize vaccine efficacy, especially for HIV and cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12232042      PMCID: PMC130579          DOI: 10.1073/pnas.192251199

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

1.  CD4(+) Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice.

Authors:  Y Ikehara; Y Yasunami; S Kodama; T Maki; M Nakano; T Nakayama; M Taniguchi; S Ikeda
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

2.  Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL.

Authors:  I M Belyakov; J D Ahlers; J D Clements; W Strober; J A Berzofsky
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

Review 3.  Anti-HIV cellular immunity: recent advances towards vaccine design.

Authors:  P J Goulder; S L Rowland-Jones; A J McMichael; B D Walker
Journal:  AIDS       Date:  1999       Impact factor: 4.177

Review 4.  New insights and approaches regarding B- and T-cell epitopes in HIV vaccine design.

Authors:  J Oscherwitz; F M Gotch; K B Cease; J A Berzofsky
Journal:  AIDS       Date:  1999       Impact factor: 4.177

5.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

Authors:  J P Ridge; F Di Rosa; P Matzinger
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

6.  Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization.

Authors:  R B Mendoza; M J Cantwell; T J Kipps
Journal:  J Immunol       Date:  1997-12-15       Impact factor: 5.422

7.  Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence.

Authors:  J D Ahlers; T Takeshita; C D Pendleton; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

8.  The role of CD4+ T cell help and CD40 ligand in the in vitro expansion of HIV-1-specific memory cytotoxic CD8+ T cell responses.

Authors:  M A Ostrowski; S J Justement; L Ehler; S B Mizell; S Lui; J Mican; B D Walker; E K Thomas; R Seder; A S Fauci
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

9.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

Authors:  S R Bennett; F R Carbone; F Karamalis; R A Flavell; J F Miller; W R Heath
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

10.  CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site.

Authors:  K H Sonoda; M Exley; S Snapper; S P Balk; J Stein-Streilein
Journal:  J Exp Med       Date:  1999-11-01       Impact factor: 14.307

View more
  30 in total

Review 1.  Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; SangKon Oh; Igor M Belyakov; Jeffrey D Ahlers; John E Janik; John C Morris
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 2.  Strategies to use immune modulators in therapeutic vaccines against cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; Lauren V Wood
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

3.  Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.

Authors:  Igor M Belyakov; Vladimir A Kuznetsov; Brian Kelsall; Dennis Klinman; Marcin Moniuszko; Michael Lemon; Phillip D Markham; Ranajit Pal; John D Clements; Mark G Lewis; Warren Strober; Genoveffa Franchini; Jay A Berzofsky
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

Review 4.  Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.

Authors:  F M Hofman; A Stathopoulos; C A Kruse; T C Chen; V E J C Schijns
Journal:  Anticancer Agents Med Chem       Date:  2010-07       Impact factor: 2.505

5.  Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models.

Authors:  Ruijiang Song; Shuqin Liu; Robert J Adams; Kam W Leong
Journal:  J Interferon Cytokine Res       Date:  2006-06       Impact factor: 2.607

6.  Vaccine-induced myeloid cell population dampens protective immunity to SIV.

Authors:  Yongjun Sui; Alison Hogg; Yichuan Wang; Blake Frey; Huifeng Yu; Zheng Xia; David Venzon; Katherine McKinnon; Jeremy Smedley; Mercy Gathuka; Dennis Klinman; Brandon F Keele; Sol Langermann; Linda Liu; Genoveffa Franchini; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2014-05-16       Impact factor: 14.808

Review 7.  A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses.

Authors:  Jay A Berzofsky
Journal:  Vaccine       Date:  2011-11-21       Impact factor: 3.641

Review 8.  Memories that last forever: strategies for optimizing vaccine T-cell memory.

Authors:  Jeffrey D Ahlers; Igor M Belyakov
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

Review 9.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 10.  Progress on new vaccine strategies against chronic viral infections.

Authors:  Jay A Berzofsky; Jeffrey D Ahlers; John Janik; John Morris; SangKon Oh; Masaki Terabe; Igor M Belyakov
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.